Loading...

Nachrichtenliste

Bayer’s new symptomatic chronic heart failure treatment Verquvo™ (vericiguat) approved in EU

2021-07-26


Bayer’s new symptomatic chronic heart failure treatment Verquvo™ (vericiguat) approved in EU

Berlin, Germany, July 21, 2021 – The European Commission has granted marketing authorization in the European Union (EU) for vericiguat under the brand name Verquvo™. Verquvo (2.5 mg, 5 mg, and 10 mg), a soluble guanylate cyclase (sGC) stimulator, is indicated for symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event requiring intravenous (IV) therapy. It works differently to existing heart failure treatments, providing a specific approach to managing chronic heart failure patients following a decompensation event, also known as a worsening event.

Wir möchten Cookies verwenden, um Ihre Nutzung dieser Website besser zu verstehen und Ihre Erfahrung bei zukünftigen Besuchen der Website zu verbessern. Sie können diese Einstellung in Ihren Browsereinstellungen ändern. Weitere Informationen zur Verwendung von Cookies finden Sie in unserer Datenschutzrichtlinie.